Claudette Bethune

1.1k total citations · 1 hit paper
20 papers, 812 citations indexed

About

Claudette Bethune is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Claudette Bethune has authored 20 papers receiving a total of 812 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Genetics and 6 papers in Oncology. Recurrent topics in Claudette Bethune's work include Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers), Cancer therapeutics and mechanisms (5 papers) and Mast cells and histamine (5 papers). Claudette Bethune is often cited by papers focused on Coagulation, Bradykinin, Polyphosphates, and Angioedema (6 papers), Cancer therapeutics and mechanisms (5 papers) and Mast cells and histamine (5 papers). Claudette Bethune collaborates with scholars based in United States, Canada and Netherlands. Claudette Bethune's co-authors include Sanjay Bhanot, Jeffrey I. Weitz, Brett P. Monia, David Gailani, Gary E. Raskob, Harry R. Büller, Peter Verhamme, Annelise Segers, Anne‐Katrine Lundebye and Richard S. Geary and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Claudette Bethune

20 papers receiving 789 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

2014 455 citations Harry R. Büller, Claudette Bethune et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claudette Bethune United States	12	374	323	237	141	139	20	812
P. Hopmeier Austria	16	295 0.8×	375 1.2×	103 0.4×	156 1.1×	35 0.3×	41	852
J Hauert Switzerland	16	104 0.3×	332 1.0×	317 1.3×	44 0.3×	152 1.1×	37	973
Margherita Scapin Italy	12	212 0.6×	227 0.7×	30 0.1×	111 0.8×	28 0.2×	18	535
Wojciech P. Mielicki Poland	13	79 0.2×	234 0.7×	51 0.2×	21 0.1×	145 1.0×	38	478
Galina Shamayeva United States	9	205 0.5×	344 1.1×	27 0.1×	147 1.0×	15 0.1×	16	549
Paula S. Howes United States	7	151 0.4×	258 0.8×	24 0.1×	119 0.8×	13 0.1×	9	451
D Lauri Italy	14	39 0.1×	101 0.3×	92 0.4×	19 0.1×	56 0.4×	25	733
Sonia Carturan Italy	17	295 0.8×	444 1.4×	52 0.2×	107 0.8×	4 0.0×	44	1.2k
Hsi-Min Hsiao United States	15	18 0.0×	84 0.3×	126 0.5×	157 1.1×	39 0.3×	17	950

Countries citing papers authored by Claudette Bethune

Since Specialization

Citations

This map shows the geographic impact of Claudette Bethune's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudette Bethune with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudette Bethune more than expected).

Fields of papers citing papers by Claudette Bethune

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudette Bethune. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudette Bethune. The network helps show where Claudette Bethune may publish in the future.

Co-authorship network of co-authors of Claudette Bethune

This figure shows the co-authorship network connecting the top 25 collaborators of Claudette Bethune. A scholar is included among the top collaborators of Claudette Bethune based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudette Bethune. Claudette Bethune is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Willmann, Stefan, Alexander Solms, Markus Jensen, et al.. (2021). PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients. CPT Pharmacometrics & Systems Pharmacology. 10(8). 890–901. 36 indexed citations

Walsh, Michael, Claudette Bethune, Andrew Smyth, et al.. (2021). Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD. Kidney International Reports. 7(2). 200–209. 62 indexed citations

Bethune, Claudette, et al.. (2017). Pharmacokinetics and Pharmacodynamics of Ionis-FXIRx, an Antisense Inhibitor of Factor XI, in Patients with End-Stage Renal Disease on Hemodialysis. Blood. 130. 1116–1116. 18 indexed citations

Luu, Kenneth T., Erin Morgan, Sanjay Bhanot, et al.. (2017). Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model. Journal of Pharmacokinetics and Pharmacodynamics. 44(3). 179–191. 11 indexed citations

Büller, Harry R., Claudette Bethune, Sanjay Bhanot, et al.. (2014). Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. New England Journal of Medicine. 372(3). 232–240. 455 indexed citations breakdown →

Büller, Harry R., Claudette Bethune, Sanjay Bhanot, et al.. (2014). Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis. Blood. 124(21). LBA–1. 7 indexed citations

Jones, Nicholas, Melissa A. Pegues, Mark A. McCrory, et al.. (2012). A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans. Molecular Therapy — Nucleic Acids. 1. e52–e52. 39 indexed citations

Liu, Que, et al.. (2011). ISIS-FXIRx, A Novel and Specific Antisense Inhibitor of Factor XI, Caused Significant Reduction in FXI Antigen and Activity and Increased aPTT without Causing Bleeding in Healthy Volunteers. Blood. 118(21). 209–209. 35 indexed citations

Sausville, Edward A., et al.. (2010). Phase I study of XMT-1001 given IV every 3 weeks to patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). e13121–e13121. 9 indexed citations

10.

Fram, Robert J., Lawrence Garbo, Glen J. Weiss, et al.. (2010). 570 Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an IV infusion every 3 weeks to patients with advanced solid tumors. European Journal of Cancer Supplements. 8(7). 180–180. 3 indexed citations

11.

Sausville, E. A., et al.. (2009). A phase I study of the safety and pharmacokinetics (PK) of XMT-1001 given as an intravenous (IV) infusion once every three weeks to patients with advanced solid tumors. Journal of Clinical Oncology. 27(15_suppl). 2574–2574. 2 indexed citations

12.

Sausville, Edward A., Lawrence Garbo, Glen J. Weiss, et al.. (2009). Abstract B52: Phase 1 study of XMT-1001, a novel water soluble camptothecin conjugate, given as an intravenous infusion once every three weeks to patients with advanced solid tumors. Molecular Cancer Therapeutics. 8(12_Supplement). B52–B52. 2 indexed citations

13.

Sausville, Edward A., Stephen P. Anthony, Lawrence Garbo, et al.. (2007). A phase I study of the safety, tolerability, and pharmacokinetics of intravenous XMT-1001 in patients with advanced solid tumors.. 6. 3 indexed citations

14.

Bethune, Claudette, Odd Johansen, Harald Arnesen, et al.. (2006). Dietary intake of differently fed salmon: a preliminary study on contaminants. European Journal of Clinical Investigation. 36(3). 193–201. 30 indexed citations

15.

Amlund, Heidi, Kevin A. Francesconi, Claudette Bethune, Anne‐Katrine Lundebye, & Marc H.G. Berntssen. (2006). Accumulation and elimination of dietary arsenobetaine in two species of fish, Atlantic salmon (Salmo salarL.) and Atlantic cod (Gadus morhuaL.). Environmental Toxicology and Chemistry. 25(7). 1787–1794. 46 indexed citations

16.

Bethune, Claudette, Kåre Julshamn, & Anne‐Katrine Lundebye. (2005). A preliminary comparison of polybrominated diphenyl ether concentrations relative to lipid content and to levels of dioxins and dioxin-like polychlorinated biphenyls in Norwegian farmed Atlantic salmon (Salmo salar). International Journal of Food Science & Technology. 40(2). 143–148. 22 indexed citations

17.

Bethune, Claudette, et al.. (2001). The Role of Drug-Lipid Interactions on the Disposition of Liposome-Formulated Opioid Analgesics In Vitro and In Vivo. Anesthesia & Analgesia. 93(4). 928–933. 11 indexed citations

18.

Bethune, Claudette, Russell Geyer, Alexander M. Spence, & Rodney J. Y. Ho. (2001). Lipid association improves the therapeutic index of lomustine [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] to suppress 36B-10 tumor growth in rats.. PubMed. 61(9). 3669–74. 12 indexed citations

19.

Bethune, Claudette, Aleksander Blum, J. Russell Geyer, John R. Silber, & Rodney J. Y. Ho. (1999). Lipid Association Increases the Potency Against Primary Medulloblastoma Cells and Systemic Exposure of l-(2-Chloroethyl)-3-Cyclohexyl-1-Nitrosourea (CCNU) in Rats. Pharmaceutical Research. 16(6). 896–903. 7 indexed citations

20.

Bethune, Claudette, et al.. (1997). Development of a high-performance liquid chromatographic assay for G418 sulfate (Geneticin). Antimicrobial Agents and Chemotherapy. 41(3). 661–664. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact